{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:16:43Z","timestamp":1788283003196,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Ruesch Center for the Cure of Gastrointestinal Cancers"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00432-022-04115-w","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T14:04:02Z","timestamp":1656597842000},"page":"2559-2574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["TKIs beyond immunotherapy predict improved survival in advanced HCC"],"prefix":"10.1007","volume":"149","author":[{"given":"Samantha","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9065-7601","authenticated-orcid":false,"given":"Tina","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Kulasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Shaukat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4100-9899","authenticated-orcid":false,"given":"Xue","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongkun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena C.","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion L.","family":"Hartley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2104-0816","authenticated-orcid":false,"given":"Aiwu Ruth","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"issue":"1","key":"4115_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40364-021-00348-y","volume":"9","author":"H Ao","year":"2021","unstructured":"Ao H, Xin Z, Jian Z (2021) Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma. Biomark Res 9(1):91. https:\/\/doi.org\/10.1186\/s40364-021-00348-y","journal-title":"Biomark Res"},{"issue":"6","key":"4115_CR2","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000518048","volume":"10","author":"T Aoki","year":"2021","unstructured":"Aoki T, Nishida N, Ueshima K et al (2021) Higher enhancement intrahepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a poor responsive marker of anti-PD-1\/PD-L1 monotherapy for unresectable hepatocellular carcinoma. Liver Cancer 2021 10(6):615\u2013628. https:\/\/doi.org\/10.1159\/000518048","journal-title":"Liver Cancer 2021"},{"key":"4115_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2018.11.031","volume":"108","author":"M Auvray","year":"2019","unstructured":"Auvray M, Auclin E, Barthelemy P et al (2019) Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer 108:33\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.031 (Erratum in: Eur J Cancer 2019; 119:200-201)","journal-title":"Eur J Cancer"},{"key":"4115_CR4","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/hep.25637","volume":"56","author":"D Bettinger","year":"2012","unstructured":"Bettinger D, Schulthei\u00df M, Knuppel E, Thimme R, Blum H, Spangenberg H (2012) Diarrhoea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology 56:789. https:\/\/doi.org\/10.1002\/hep.25637","journal-title":"Hepatology"},{"issue":"7","key":"4115_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kjms.2018.03.006","volume":"34","author":"WT Chang","year":"2018","unstructured":"Chang WT, Lu SN, Rau KM, Huang CS, Lee KT (2018) Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. Kaohsiung J Med Sci 34(7):391\u2013399. https:\/\/doi.org\/10.1016\/j.kjms.2018.03.006","journal-title":"Kaohsiung J Med Sci"},{"issue":"1","key":"4115_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(08;70285-7","volume":"10","author":"A Cheng","year":"2009","unstructured":"Cheng A, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase iii randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25\u201334. https:\/\/doi.org\/10.1016\/s1470-2045(08;70285-7","journal-title":"Lancet Oncol"},{"key":"4115_CR7","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/liv.12168","volume":"33","author":"J Cho","year":"2013","unstructured":"Cho J, Paik Y, Lim H et al (2013) Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int 33:950\u2013957. https:\/\/doi.org\/10.1111\/liv.12168","journal-title":"Liver Int"},{"key":"4115_CR8","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337\u2013345. https:\/\/doi.org\/10.1056\/NEJMoa033025","journal-title":"N Engl J Med"},{"key":"4115_CR9","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2217\/fon.14.291","volume":"11","author":"G Di Costanzo","year":"2015","unstructured":"Di Costanzo G, De Stefano G, Tortora R et al (2015) Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncol 11:943\u2013951. https:\/\/doi.org\/10.2217\/fon.14.291","journal-title":"Future Oncol"},{"key":"4115_CR10","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/bjc.2011.507","volume":"105","author":"F Di Fiore","year":"2011","unstructured":"Di Fiore F, Rigal O, M\u00e9nager C, Michel P, Pfister C (2011) Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br J Cancer 105:1811\u20131813. https:\/\/doi.org\/10.1038\/bjc.2011.507","journal-title":"Br J Cancer"},{"issue":"10088","key":"4115_CR11","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/s0140-6736(17)31046-2","volume":"389","author":"A El-Khoueiry","year":"2017","unstructured":"El-Khoueiry A, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389(10088):2492\u20132502. https:\/\/doi.org\/10.1016\/s0140-6736(17)31046-2","journal-title":"Lancet"},{"issue":"18","key":"4115_CR12","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K et al (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124(18):3706\u20133714. https:\/\/doi.org\/10.1002\/cncr.31629","journal-title":"Cancer"},{"issue":"8","key":"4115_CR13","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2018","unstructured":"Ferlay J, Colombet M, Soerjomataram I et al (2018) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941\u20131953. https:\/\/doi.org\/10.1002\/ijc.31937","journal-title":"Int J Cancer"},{"issue":"15","key":"4115_CR14","doi-asserted-by":"publisher","first-page":"suppl.4004","DOI":"10.1200\/jco.2019.37.15_suppl.4004","volume":"37","author":"R Finn","year":"2019","unstructured":"Finn R, Ryoo B, Merle P et al (2019) Results of KEYNOTE-240: phase 3 study of pembrolizumab (pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol 37(15):suppl.4004. https:\/\/doi.org\/10.1200\/jco.2019.37.15_suppl.4004","journal-title":"J Clin Oncol"},{"issue":"20","key":"4115_CR15","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/nejmoa1915745","volume":"382","author":"R Finn","year":"2020","unstructured":"Finn R, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl Jo Med 382(20):1894\u20131905. https:\/\/doi.org\/10.1056\/nejmoa1915745","journal-title":"N Engl Jo Med"},{"key":"4115_CR16","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1200\/JCO.2012.45.3068","volume":"31","author":"D Fontein","year":"2013","unstructured":"Fontein D, Seynaeve C, Hadji P et al (2013) Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31:2257\u20132264. https:\/\/doi.org\/10.1200\/JCO.2012.45.3068","journal-title":"J Clin Oncol"},{"issue":"12","key":"4115_CR17","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.3748\/wjg.v20.i12.3087","volume":"20","author":"D Germano","year":"2014","unstructured":"Germano D, Daniele B (2014) Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J Gastroenterol 20(12):3087\u20133099. https:\/\/doi.org\/10.3748\/wjg.v20.i12.3087","journal-title":"World J Gastroenterol"},{"key":"4115_CR18","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/annonc\/mdq221","volume":"21","author":"R Goodwin","year":"2010","unstructured":"Goodwin R, Ding K, Seymour L et al (2010) Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC clinical trials group study BR24. Ann Oncol 21:2220\u20132226. https:\/\/doi.org\/10.1093\/annonc\/mdq221","journal-title":"Ann Oncol"},{"key":"4115_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cncr.28972","volume":"121","author":"O Hamnvik","year":"2015","unstructured":"Hamnvik O, Choueiri T, Turchin A et al (2015) Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 121:311\u2013319. https:\/\/doi.org\/10.1002\/cncr.28972","journal-title":"Cancer"},{"issue":"5","key":"4115_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1159\/000501281","volume":"97","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Atsukawa M, Real-life Practice Experts for HCC (RELPEC) Study Group; HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) et al (2019) Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma. Oncology 97(5):277\u2013285. https:\/\/doi.org\/10.1159\/000501281 (Epub 2019 Jul 15)","journal-title":"Oncology"},{"issue":"8","key":"4115_CR21","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/apt.13977","volume":"45","author":"J Howell","year":"2017","unstructured":"Howell J, Pinato DJ, Ramaswami R et al (2017) On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study. Aliment Pharmacol Ther 45(8):1146\u20131155. https:\/\/doi.org\/10.1111\/apt.13977","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"4115_CR22","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/diseases3040360","volume":"3","author":"M Ikeda","year":"2015","unstructured":"Ikeda M, Mitsunaga S, Ohno I et al (2015) Systemic chemotherapy for advanced hepatocellular carcinoma: past, present, and future. Diseases 3(4):360\u2013381. https:\/\/doi.org\/10.3390\/diseases3040360 (Published 2015 Dec 1)","journal-title":"Diseases"},{"issue":"10","key":"4115_CR23","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.3390\/cancers12102859","volume":"12","author":"C Kole","year":"2020","unstructured":"Kole C, Charalampakis N, Tsakatikas S et al (2020) Immunotherapy for hepatocellular carcinoma: a 2021 update. Cancers (basel) 12(10):2859. https:\/\/doi.org\/10.3390\/cancers12102859","journal-title":"Cancers (basel)"},{"key":"4115_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1159\/000342425","volume":"84","author":"R Koschny","year":"2013","unstructured":"Koschny R, Gotthardt D, Koehler C, Jaeger D (2013) Diarrhoea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology 84:6\u201313. https:\/\/doi.org\/10.1159\/000342425","journal-title":"Oncology"},{"issue":"10126","key":"4115_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet"},{"key":"4115_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"issue":"4","key":"4115_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000516899","volume":"10","author":"M Morita","year":"2021","unstructured":"Morita M, Nishida N, Sakai K et al (2021) Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody. Liver Cancer 10(4):380\u2013393. https:\/\/doi.org\/10.1159\/000516899","journal-title":"Liver Cancer"},{"issue":"3","key":"4115_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"Osorio JC, Ni A, Chaft JE et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583\u2013589. https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann Oncol"},{"key":"4115_CR29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/j.1872-034X.2012.00991","volume":"42","author":"T Otsuka","year":"2012","unstructured":"Otsuka T, Eguchi Y, Kawazoe S, Yanagita K, Ario K, Kitahara K (2012) Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 42:879\u2013886. https:\/\/doi.org\/10.1111\/j.1872-034X.2012.00991","journal-title":"Hepatol Res"},{"key":"4115_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejca.2019.04.003","volume":"114","author":"AY Shah","year":"2019","unstructured":"Shah AY, Kotecha RR, Lemke EA et al (2019) Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114:67\u201375. https:\/\/doi.org\/10.1016\/j.ejca.2019.04.003","journal-title":"Eur J Cancer"},{"issue":"1","key":"4115_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4115_CR32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III\u2013IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33(7):773\u2013781. https:\/\/doi.org\/10.1200\/JCO.2014.57.4756","journal-title":"J Clin Oncol"},{"key":"4115_CR33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1634\/theoncologist.2009-0143","volume":"15","author":"B Vincenzi","year":"2010","unstructured":"Vincenzi B, Santini D, Russo A, Addeo R (2010) Early skin toxicity as a predictive factor for tumour control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 15:85\u201392. https:\/\/doi.org\/10.1634\/theoncologist.2009-0143","journal-title":"Oncologist"},{"issue":"1","key":"4115_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40425-018-0346-6","volume":"6","author":"Y Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E et al (2018) Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 6(1):37. https:\/\/doi.org\/10.1186\/s40425-018-0346-6","journal-title":"J Immunother Cancer"},{"issue":"15","key":"4115_CR35","doi-asserted-by":"publisher","first-page":"suppl.4012","DOI":"10.1200\/JCO.2019.37.15_suppl.4012","volume":"37","author":"T Yau","year":"2019","unstructured":"Yau T, Kang YK, Kim TY et al (2019a) Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (patients) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol 37(15):suppl.4012. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.4012","journal-title":"J Clin Oncol"},{"key":"4115_CR36","doi-asserted-by":"publisher","first-page":"v874","DOI":"10.1093\/annonc\/mdz394.029","volume":"30","author":"T Yau","year":"2019","unstructured":"Yau T, Park JW, Finn RS et al (2019b) CheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (patients) with advanced hepatocellular carcinoma (AHCC). Ann Oncol 30:v874\u2013v875. https:\/\/doi.org\/10.1093\/annonc\/mdz394.029","journal-title":"Ann Oncol"},{"issue":"20","key":"4115_CR37","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/jnci\/dji315Zhu","volume":"97","author":"W Yeo","year":"2005","unstructured":"Yeo W, Mok TS, Zee B et al (2005) A randomized phase III study of doxorubicin versus cisplatin\/interferon alpha-2b\/doxorubicin\/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97(20):1532\u20131538. https:\/\/doi.org\/10.1093\/jnci\/dji315Zhu","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"4115_CR38","doi-asserted-by":"publisher","first-page":"suppl.TSP504","DOI":"10.1200\/jco.2017.35.4_suppl.tps504","volume":"35","author":"A Zhu","year":"2017","unstructured":"Zhu A, Knox J, Kudo M et al (2017) KEYNOTE-224: phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma. J Clin Oncol 35(4):suppl.TSP504. https:\/\/doi.org\/10.1200\/jco.2017.35.4_suppl.tps504","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04115-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04115-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04115-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T06:09:54Z","timestamp":1682402994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04115-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["4115"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04115-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"27 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Samantha Armstrong declares that she has no conflict of interest. Tina Roy declares that she has no conflict of interest. Bhavana Singh declares that she has no conflict of interest. Monika Kulasekaran declares that she has no conflict of interest. Fatima Shaukat declares that she has no conflict of interest. Xue Geng declares that she has no conflict of interest. Hongkun Wang declares that she has no conflict of interest. Petra Prins declares that she has no conflict of interest. Reena C. Jha declares that she has no conflict of interest. Marion L. Hartley, PhD declares that she has no conflict of interest. Aiwu Ruth He declares that she has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}